Preeclampsia — Standard 24-hour Urine Protein vs Shorter Period for Diagnosis of Pre-eclampsia
Citation(s)
Adelberg AM, Miller J, Doerzbacher M, Lambers DS Correlation of quantitative protein measurements in 8-, 12-, and 24-hour urine samples for the diagnosis of preeclampsia. Am J Obstet Gynecol. 2001 Oct;185(4):804-7. doi: 10.1067/mob.2001.117302.
Shennan AH, Redman C, Cooper C, Milne F Are most maternal deaths from pre-eclampsia avoidable? Lancet. 2012 May 5;379(9827):1686-7. doi: 10.1016/S0140-6736(11)60785-X. Epub 2011 Dec 14. No abstract available.
Tun C, Quinones JN, Kurt A, Smulian JC, Rochon M Comparison of 12-hour urine protein and protein:creatinine ratio with 24-hour urine protein for the diagnosis of preeclampsia. Am J Obstet Gynecol. 2012 Sep;207(3):233.e1-8. doi: 10.1016/j.ajog.2012.06.010. Epub 2012 Jun 11.
Comparison of the Standard 24-hour Urine Protein With Shorter Collection Periods for the Diagnosis of Preeclampsia
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
